In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in the Biden administration continues.
While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs — which account for 90% of U.S. prescriptions — see trouble ahead for patients.
President Trump wants to lower drug prices in the U.S. by tying them to the prices paid in other developed countries. The pharmaceutical industry has long opposed the approach.
The interim U.S. attorney for the District of Columbia has sent letters to several leading medical journals asking for information about their editorial practices.
Some lawmakers are pushing to require that Medicaid recipients work in order to get or keep coverage, and some states already try to help them find jobs. But the effects of those efforts are unclear.
Health care price transparency is one of the few bipartisan issues in Washington, D.C. But much of the information is not helpful to patients, and there's no evidence that it's lowering costs.
The law originally banned health care providers from forcing patients to agree to pay medical bills, no matter the cost. Consumer groups say an amended version doesn't go far enough.
The U.S. already faced shortages in its health care workforce, then the pandemic spurred even more doctors and nurses to retire or leave hospital jobs. Filling those vacancies is a challenge.
Hoping to bring the giant, ancient animal back from extinction, scientists have created a far smaller woolly creature. Woolly mice have some of the key traits of mammoths, including their thick, hairy coat.
January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including Ozempic, drugs for HIV, cancer and many others.
The man charged in the killing of UnitedHealthcare CEO Brian Thompson was critical of U.S. health care. Experts say the system's problems are complex and can't be pinned on one player or industry.
